Reduced Costs and Continued Cures Act

Bill: 117-hr-5260
Sponsor: Rep. Peters, Scott H. [D-CA-52]
Introduced: 2021-09-14 in the House
Policy area: Health
Subjects: Accounting and auditing
Administrative law and regulatory procedures
Administrative remedies
Appropriations
Civil actions and liability
Competition and antitrust
Congressional oversight
Consumer affairs
Contracts and agency
Department of Health and Human Services
Digestive and metabolic diseases
Drug safety, medical device, and laboratory regulation
Drug therapy
Federal Trade Commission (FTC)
Genetics
Government studies and investigations
Health care costs and insurance
Health care coverage and access
Health care quality
Health programs administration and funding
Health technology, devices, supplies
Home and outpatient care
Inflation and prices
Intellectual property
Intergovernmental relations
Judicial review and appeals
Licensing and registrations
Manufacturing
Marketing and advertising
Medicaid
Medicare
Performance measurement
Prescription drugs
Public contracts and procurement
State and local government operations

Summary:
action_date: 2021-09-14
text: 

Reduced Costs and Continued Cures Act

 
This bill establishes and alters several programs and requirements relating to the prices of prescription drugs. 
 
For example, the bill establishes and alters several requirements under Medicare and Medicaid, including
 
 
requiring drug manufacturers to issue rebates to the Centers for Medicare & Medicaid Services for covered drugs under Medicare that cost $100 or more and for which the average manufacturer price increases faster than inflation,
 
capping annual out-of-pocket spending under the Medicare prescription drug benefit, and
 
increasing the maximum rebate amount under the Medicaid Drug Rebate Program.
 
 
The bill also makes changes relating to market exclusivities and manufacturer price concessions for prescription drugs, including 
 
 
authorizing the Federal Trade Commission to initiate proceedings against parties to settlements of patent infringement claims that have anticompetitive effects with respect to drugs or biologics,
 
limiting in certain instances the number of patents that the manufacturer of a biologic can assert in a lawsuit against a company seeking to sell a biosimilar version, and
 
nullifying regulations relating to the treatment of certain Medicare prescription drug benefit rebates from drug manufacturers for purposes of federal anti-kickback laws.
 


Legislative actions:
action_date: 2022-11-01
text: Referred to the Subcommittee on Courts, Intellectual Property, and the Internet.
action_date: 2022-11-01
text: Referred to the Subcommittee on Antitrust, Commercial, and Administrative Law.
action_date: 2021-09-15
text: Referred to the Subcommittee on Health.
action_date: 2021-09-14
text: Referred to the Subcommittee on Health.
action_date: 2021-09-14
text: Referred to the Committee on Energy and Commerce, and in addition to the Committees on Ways and Means, and the Judiciary, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
action_date: 2021-09-14
text: Referred to the Committee on Energy and Commerce, and in addition to the Committees on Ways and Means, and the Judiciary, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
action_date: 2021-09-14
text: Referred to the Committee on Energy and Commerce, and in addition to the Committees on Ways and Means, and the Judiciary, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
action_date: 2021-09-14
text: Introduced in House
action_date: 2021-09-14
text: Introduced in House